An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor

Nicholas G. Wysham, Donald Sullivan, Gopal Allada

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.

Original languageEnglish (US)
Pages (from-to)1478-1479
Number of pages2
JournalChest
Volume143
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Janus Kinase 1
Janus Kinase 2
Opportunistic Infections
Primary Myelofibrosis
Cryptococcus neoformans
Cellular Immunity
Pneumonia
Infection
Pharmaceutical Preparations
INCB018424
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. / Wysham, Nicholas G.; Sullivan, Donald; Allada, Gopal.

In: Chest, Vol. 143, No. 5, 05.2013, p. 1478-1479.

Research output: Contribution to journalArticle

@article{d452a8188c2a49219bb4d590095306b1,
title = "An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor",
abstract = "We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.",
author = "Wysham, {Nicholas G.} and Donald Sullivan and Gopal Allada",
year = "2013",
month = "5",
doi = "10.1378/chest.12-1604",
language = "English (US)",
volume = "143",
pages = "1478--1479",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5",

}

TY - JOUR

T1 - An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor

AU - Wysham, Nicholas G.

AU - Sullivan, Donald

AU - Allada, Gopal

PY - 2013/5

Y1 - 2013/5

N2 - We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.

AB - We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.

UR - http://www.scopus.com/inward/record.url?scp=84877618100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877618100&partnerID=8YFLogxK

U2 - 10.1378/chest.12-1604

DO - 10.1378/chest.12-1604

M3 - Article

C2 - 23648912

AN - SCOPUS:84877618100

VL - 143

SP - 1478

EP - 1479

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5

ER -